Beyond Jakafi: What Ipsen's $1.75 Billion Bet on Navtemadlin Means for Myelofibrosis Treatment

For most patients diagnosed with myelofibrosis, the treatment conversation begins and ends with one drug. Ruxolitinib, sold as Jakafi by Incyte and marketed by Novartis outside the United States, has been the standard of care in this rare blood cancer for over a decade. It reduces spleen size, alleviates the crushing symptom burden of fatigue, night sweats, and bone pain, and extends survival. It is a genuinely useful drug. It is also, for a substantial proportion of patients, not enough.

Somewhere between 50 and 75 percent of myelofibrosis patients discontinue ruxolitinib within three years, either because the drug stops working or because it never worked well enough to begin with. When that happens, the prognosis deteriorates sharply. Median overall survival after ruxolitinib discontinuation is approximately one to two years. The field has second-line options, including fedratinib and pacritinib, but none of them have fundamentally changed the trajectory of the disease for patients who have already failed the standard of care. That gap is what Ipsen is paying $1.75 billion to address.

The Deal and What It Signals

On June 29, 2026, Ipsen announced it had entered into a definitive merger agreement to acquire Kartos Therapeutics, a clinical-stage biotech based in Redwood City, California. The terms: $450 million upfront, with up to $1.3 billion in additional milestone payments including a significant regulatory approval milestone and sales-based thresholds. The transaction is expected to close by the end of Q3 2026, pending standard antitrust review. Ipsen CEO David Loew framed the acquisition as an opportunity to "define a new treatment paradigm" for myelofibrosis patients who have a suboptimal response to current standard of care, with a potential new therapeutic option available as early as 2028.

What Ipsen is acquiring is navtemadlin, an oral MDM2 inhibitor that has been in development since Kartos was founded in 2018 specifically to advance this compound. The drug is currently in a global Phase III trial called POIESIS, designed to enroll more than 600 patients across more than 250 sites worldwide. Topline data are expected in 2027. If those data are positive, navtemadlin could become the first drug approved specifically for myelofibrosis patients who have failed ruxolitinib through a mechanism entirely distinct from JAK inhibition.

The Science Behind the Strategy

Understanding why navtemadlin is interesting requires a brief detour into tumor biology. MDM2 is a protein that functions as a negative regulator of p53, one of the most important tumor suppressor proteins in the human genome. Under normal circumstances, p53 monitors cellular stress and DNA damage, triggering cell cycle arrest or apoptosis when something goes wrong. MDM2 keeps p53 in check by binding to it and marking it for degradation. In many cancers, MDM2 is overexpressed, effectively silencing p53 and allowing damaged cells to proliferate unchecked.

Navtemadlin works by blocking the MDM2-p53 interaction, freeing p53 to resume its tumor-suppressing function. The approach is not new in oncology, but its application to myelofibrosis is relatively recent and scientifically compelling. More than 95 percent of myelofibrosis patients have TP53 wild-type disease, meaning their p53 gene is intact and functional. The problem is not a broken p53 gene. It is an overactive MDM2 that is suppressing a working tumor suppressor. Navtemadlin is designed to release that suppression.

The Phase 1b/2 data that supported the POIESIS trial design are encouraging. In 19 patients with myelofibrosis who had a suboptimal response to ruxolitinib, navtemadlin added to ongoing ruxolitinib produced a 42 percent rate of at least 25 percent spleen volume reduction at Week 24, and 32 percent achieved at least a 35 percent reduction. More striking were the disease modification signals: 71 percent of evaluable patients achieved a 20 percent or greater reduction in driver variant allele frequency, a molecular marker of disease burden, and 57 percent showed improvement in bone marrow fibrosis by at least one grade. Those are not just symptomatic improvements. They suggest navtemadlin may be doing something to the underlying biology of the disease that ruxolitinib alone cannot accomplish.

Why the Combination Approach Matters

The strategic logic of navtemadlin as an add-on to ruxolitinib rather than a replacement for it deserves attention. The conventional approach to drug development in myelofibrosis has been to find better JAK inhibitors or to sequence patients through available options as each one fails. Navtemadlin represents a different philosophy: rather than competing with ruxolitinib, it is designed to work alongside it, targeting a complementary pathway to deepen responses in patients who are already on the standard of care but not getting enough benefit from it.

This combination strategy has precedent in oncology. The most successful cancer treatment advances of the past decade have often come not from replacing existing therapies but from adding agents that address the mechanisms of resistance or incomplete response. The question for navtemadlin is whether the Phase 1b/2 signals hold up in a randomized, controlled Phase III setting. The POIESIS trial is designed to answer that question rigorously, with a primary endpoint focused on clinically meaningful spleen volume reduction and symptom improvement in patients who have already demonstrated a suboptimal response to ruxolitinib.

The Competitive Landscape and What Comes Next

Ipsen is not the only company pursuing the post-ruxolitinib myelofibrosis space. Bristol Myers Squibb's fedratinib and CTI BioPharma's pacritinib are both approved for patients who have failed or are intolerant to ruxolitinib, and Sierra Oncology's momelotinib, now owned by GSK, addresses the anemia that complicates treatment in many patients. But none of these drugs target the p53 pathway, and none have demonstrated the kind of disease modification signals that navtemadlin's early data suggest.

The broader significance of this acquisition extends beyond myelofibrosis. Ipsen has been systematically building its oncology pipeline through external deals, having previously acquired antibody-drug conjugate programs and next-generation immuno-oncology assets. The Kartos acquisition adds a late-stage asset with a differentiated mechanism, a clear patient population, and a regulatory path that could deliver an approval within two years of the Phase III readout. For a mid-sized European biopharma competing in a space dominated by much larger players, that kind of pipeline acceleration through acquisition is increasingly the only viable strategy.

For patients with myelofibrosis who have exhausted their options on ruxolitinib, the POIESIS trial represents something more immediate than a corporate strategy story. It is the largest trial ever conducted in this disease, enrolling patients across 250 sites in a design that its investigators describe as reflecting real-world clinical practice. The data expected in 2027 will determine whether navtemadlin becomes the first drug to meaningfully change outcomes for the patients who need it most: those for whom the standard of care has already run its course.